Main Logo

Society for Pediatric Radiology – Poster Archive


Final ID: Poster #: SCI-032

Pediatric Theranostic Applications of Dotatate: Early Clinical Experience

Purpose or Case Report: Though pediatric use of both 68Gallium Dotatate and 177Lutetium is off label, the advantages they offer over FDA approved agents has led to their preliminary use in a variety of pediatric clinical scenarios. The purpose of this poster is to present the range of potential diagnostic and therapeutic applications of 68Gallium Dotatate in children.
Methods & Materials: Case examples were gathered by retrospective chart review focusing on 68Gallium Dotatate use in the pediatric population. Project approval from the XXX Institutional Review Board was obtained prior to data collection. Individual patient charts were reviewed to obtain relevant data including demographics, type of neuroendocrine tumor, age of diagnosis, presence/absence of predisposing hereditary syndromes, and treatment course and imaging studies were reviewed.
Results: Though its use is considered off label in children, there are several advantages of 68Gallium Dotatate PET/CT over traditional Octreoscan and MIBG scanning of neuroendocrine tumors, NET, in children. Dotatate has a far greater affinity for the somatostatin receptors these tumors often express than Octreotide which results in a greater target to background ratio and better lesion conspicuity. The various potential diagnostic uses of 68Gallium Dotatate PET/CT in children include initial staging and follow-up of NET, including neuroblastoma, esthesioneuroblastoma, paragangliom/pheochromocytoma, pulmonary and gastrointestinal carcinoid tumors and well as screening in patient groups susceptible to the development of NET, such as SDH and MEN syndromes, are discussed and examples of each are provided. Additionally, examples of its role in proton beam treatment planning are presented. Lastly, examples of radiotherapy for MIBG-negative neuroblastomas or other dotatate-positive malignacies with 177-lutetium labelled dotatate will be presented.
Conclusions: Dotatate-based imaging and therpeutic agents show great promise in the evaluation and treatment of pediatric patients with NET. Though their use is off label, the advantages they have over current standard imaging agents and the potential complimentary role to Iodine-131 MIBG therapy they offer show great promise.
Session Info:

Posters - Scientific

Nuclear Imaging/Oncology

SPR Posters - Scientific

You have to be authorized to contact abstract author. Please, Login or Signup.

Please note that this is a separate login, not connected with your credentials used for the SPR main website.

Not Available


We encourage you to join the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and stimulate conversation and knowledge sharing.

Please click here to review the full terms and conditions for engaging in the discussion, including refraining from product promotion and non-constructive feedback.


You have to be authorized to post a comment. Please, Login or Signup.

Please note that this is a separate login, not connected with your credentials used for the SPR main website.

   Rate this abstract  (Maximum characters: 500)